A key issue as we move closer to ending the pandemic is determining more precisely how long people exposed to SARS-CoV-2, the COVID-19 virus, will make neutralizing antibodies against this dangerous coronavirus. Finding the answer is also potentially complicated with new SARS-CoV-2 “variants of concern” appearing around the world that could find ways to evade acquired immunity, increasing the chances of new outbreaks.
What are essential thrombocythemia (ET) , polycythemia vera (PV), and myelofibrosis (MF) exactly? Dr. Naveen Pemmaraju explains how each of these blood disorders manifests along with the symptoms observed in these MPN patients.
Dr. Naveen Pemmaraju is Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. Learn more about Dr. Pemmaraju, here.
(Watch video at link above)
Abstract
Background
Key points
– With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH –
– Approval based on interim results from Phase 3 study showing ULTOMIRIS demonstrated complete terminal complement inhibition through 26 weeks –
Clinical psychologist Jessica Pieczynski, PhD, offers insights into how practicing mindfulness techniques can help cancer survivors manage stress during the pandemic, and beyond.
It’s possible that 2020 will go down in history as the year of Murphy’s Law. The whole “what can go wrong, will go wrong” adage seems fitting for many as they navigate the economic, social and familial impact of the pandemic and cultural movements. Increased stress during these challenging times is the norm for even the healthiest among us.
CC-486—the oral formulation of azacitidine—significantly improved RBC transfusion independence (RBC-TI) rates and induced durable bilineage improvements in patients with lower-risk
Key Points
Mesothelin is aberrantly expressed in over one third of childhood and young adult AML and not expressed on normal hematopoietic cells.
Mesothelin is successfully targeted in vitro and in xenograft models of MSLN+ AML with ADCs.
Abstract
With the goal of capitalizing on the efficacy observed with cellular therapies in acute leukemias, ongoing research efforts are underway to address unanswered questions regarding the role of transplant in conjunction with cellular therapy, optimal toxicity management, antigen escape, and methods to overcome myelosuppression and immunosuppression in these diseases, said Michael Grunwald, MD.